


## PHARMACEUTICAL 2023

## Orgenesis Inc. Rank 161 of 446







## PHARMACEUTICAL 2023

## Orgenesis Inc. Rank 161 of 446



The relative strengths and weaknesses of Orgenesis Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Orgenesis Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 57% points. The greatest weakness of Orgenesis Inc. is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 39% points.

The company's Economic Capital Ratio, given in the ranking table, is 145%, being 102% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	46,318
Cost of Goods Sold	27,066
Intangible Assets	17,881
Liabilities, Current	15,910
Liabilities, Non-Current	15,744
Other Assets	3,895
Other Compr. Net Income	-2,243
Other Expenses	2,181
Other Liabilities	0
Other Net Income	-3,358
Other Revenues	36,025
Property and Equipment	22,834
Research and Development	0
Selling, General and Administrative Expense	15,589

Output Variable	Value in 1000 USD
Assets	90,928
Liabilities	31,654
Expenses	44,836
Revenues	36,025
Stockholders Equity	59,274
Net Income	-12,169
Comprehensive Net Income	-13,290
Economic Capital Ratio	145%

